SCHEMBL12306509

SCHEMBL12306509

c1ccc(-c2ccc(-c3cccc(-c4ccc5c(c4)C4(CCCCC4)c4cc(-c6cccc(-c7ccc(-c8ccccc8)s7)c6)ccc4-5)c3)s2)cc1

nearest known ligand 0.49

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 13/20 0.49
▸ HSD17B1 P14061 3/20 0.41
▸ HSD17B2 P37059 3/20 0.41
▸ PDK2 Q15119 1/20 0.38
▸ PDE7A Q13946 1/20 0.37
▸ PRKDC P78527 1/20 0.36
▸ PRF1 P14222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12306508 0.82 ADORA1 (0.49) PGRPDK2
SCHEMBL14462949 0.81 PGR (0.39) PGRHSD17B1HSD17B2PDE7APRKDC
SCHEMBL19494826 0.80 PGR (0.51) PGRPDK2PDE7A
SCHEMBL12306512 0.79 HSD17B1 (0.46) PGRHSD17B1HSD17B2PDK2PRF1
SCHEMBL17057198 0.78 PGR (0.45) PGRPDK2PDE7A
SCHEMBL14340097 0.78 APP (0.42) PGRHSD17B1HSD17B2PDK2PRKDC
SCHEMBL12306558 0.78 HSD17B1 (0.45) PGRHSD17B1HSD17B2PDK2
SCHEMBL12306510 0.77 PGR (0.46) PGRPDK2PDE7A
SCHEMBL23767079 0.77 PGR (0.49) PGRPDK2PDE7A
SCHEMBL23767222 0.77 PGR (0.49) PGRPDK2PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8013160-B2 Fluorene-based derivative and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2011-09-06 — — US disclosed
US-8013160-B2 Fluorene-based derivative and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2011-09-06 — — US disclosed
US-20100277063-A1 FLUORENE-BASED DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2010-11-04 — — US disclosed
US-20100277063-A1 FLUORENE-BASED DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2010-11-04 — — US disclosed
US-7781628-B2 Fluorene-based derivative and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2010-08-24 — — US disclosed
US-7781628-B2 Fluorene-based derivative and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2010-08-24 — — US disclosed
US-7683225-B2 Fluorene-based derivative and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2010-03-23 — — US disclosed
US-7683225-B2 Fluorene-based derivative and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2010-03-23 — — US disclosed
US-20080303433-A1 FLUORENE-BASED DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2008-12-11 — — US disclosed
US-20080303433-A1 FLUORENE-BASED DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2008-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100277063-A1 FLUORENE-BASED DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME LEF1, FLNA, AFF2 PGR 2357/4885HSD17B1 2402/4885HSD17B2 2130/4885
US-20080303433-A1 FLUORENE-BASED DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME FLNA, AFF2, LEF1 PGR 2267/4885HSD17B1 2018/4885HSD17B2 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback